TRSL Presentation December 5, 2005 Joseph F. Lovett Louisiana Fund I Managing Director.

Slides:



Advertisements
Similar presentations
Sources of Financing Tool Kit. General sources of information Useful web Sites Inc. Magazine > vFinance.com, Inc. > –Publicly-owned financial services.
Advertisements

1 CTI Life Sciences Fund Introduction January 2008.
Presentation to Venture Association of New Jersey 3/16/04.
Shaking the MoneyTree™
California Initiative Update. 2 Mission Statement The California Initiative will invest in traditionally underserved markets primarily, but not exclusively,
Senate Education Committee Briefing Russell Ingram, Executive Director March 23, 2011.
Prize4Life: Inducement Prizes for ALS (Lou Gehrig’s Disease) Nicole Szlezak Member, Board of Directors Prize4Life.
1 CLEVELAND The Nation’s New Healthcare Innovation Destination 2011.
NCI Designation: Expanding Science and Promoting Health in the Region Name Title, Company Date.
Community College Program Welcome. Annual Community College Program Day Organizing Committee Sonia Wallman – Executive Director NBC2 Elaine Johnson –
Medical Device The Israeli Case. Objectives Drawing a general “profile” of the Israeli entrepreneur and to draw lessons on the following issues: 1. The.
Biotechnology Incubators in Israel. The Israeli Biotechnology Market 160 companies (30% in therapeutics) 4000 employees Market valuation: $3.5 billion.
Module 4 The Search for Capital. Module 4 Topics Sources of Capital Background Start-up Ongoing Operations Growth.
Funding MBAX 6100 Entrepreneurship & Small Business Funding Frank Moyes Leeds School of Business University of Colorado Boulder, Colorado.
Biotechnology The Israeli Case Definition Using living organisms, cells or biological agents, to produce goods and services. Modern biotechnology arose.
Eve E. Slater, M.D., F.A.C.C. Assistant Secretary for Health Department of Health and Human Services Fostering Innovation in Medicine and Research 2002.
1 Public Pension Funds and Targeted Investing December 6, 2006.
January 3, 2003 Kevin Rakin President and Chief Executive Officer Kevin Rakin President and Chief Executive Officer Economic Summit and Outlook 2003.
Private Equity Fund Structure - Best Practices June 24 th, 2014.
1 National Venture Capital Association 2008 Predictions Survey All data embargoed until: December 17, 2007.
1 The UK Opportunity: what is experimental medicine? UNLOCK YOUR GLOBAL BUSINESS POTENTIAL Pre- clinical develop- ment Phase I Phase II Phase III Product.
Crossroads Institute Gary Larrowe Extension Specialist VA Tech.
VENTURE CAPITAL IMPORTANT SOURCE OF EQUITY FOR HIGH GROWTH COMPANIES.
Vcapital Confidential1 Startup Workshop Presentation to.
Venture Capital and U.S. Trade Competitiveness Karen G. Mills April 4, 2005 Council on Foreign Relations How Does Innovation Translate.
Presentation by Dr. Andreas O. Tobler November 5, 2009.
Bio-Tech Israel 2005 Conference & Exhibition May 24 – 26, 2005 David Intercontinental Hotel, Tel Aviv, Israel.
Venture and Growth Capital. Equity Investments  Holding on to ‘what you’ve got’  Equity investments are a ‘trade-off’ game…
Russian Venture Company Fund of venture funds Basic terms Ministry of Economic Development and Trade Russian Federation.
Innovation Ecosystems Clare Fairfield. Key Terms Innovation Venture Capital Invention ≠ Innovation.
Role of Industry in Clinical Care, Research and Education Rev 10/21/2014 APGO Interaction with Industry: A Medical Student Guide.
Nathan Tinker Executive Director New York Biotechnology Association New York BizBio 2009 Fighting for a Healthy Biotech Industry.
Today's Investment, Tomorrow's Return - A Catalyst for Resurgence Annual Conference November 18, 2003 Terry Matthews Chairman & CEO March Networks Chairman.
Life Science Venture Capital 11th Annual NIH SBIR/STTR Conference July 1, 2009 Randy H. Weiss, Ph.D. Partner, Triathlon Medical Ventures.
850 Woodside Drive Woodside, California (650) W O O D S I D E F U N D Early Stage Investing Venture Capital Forum December.
Providing capital, knowledge & networks since Federal Laboratory Consortium Mid-Atlantic Regional Meeting Ben Franklin Technology Partners of Southeastern.
EUROPEAN PE PERFORMANCE – FIRST HALF 2011 All European Private Equity Returns Outperform Public Markets, driven by buyout funds; short-term venture returns.
Genomic Health, Inc. Yuko Soneoka, Ph.D., J.D. Senior Corporate Counsel, IP Director of Intellectual Property January 31, 2013.
Sarsia Innovation AS Sarsia Innovation as The ‘Bergen Model’ for commercialisation spans the process from identification of a promising research project.
Copyright Rib-X, Inc – All Rights Reserved Susan Froshauer, Ph.D. President and CEO.
# MCL 0 Today’s Venture Capital Environment Ted R. Woolschlager Director, Emerging Growth Markets Mid-Atlantic Area Ernst & Young June.
The State of the Massachusetts Life Science Industry - The Year in Review - June 2, 2011 MALSI | MA Life Sciences Innovation Day.
Venture Capital Club 2003/2004 Introduction September 10, 2003.
September 13, 2007SGH&M2B International&Training Workshop What does the European Technology Platform “Innovative Medicines initiative” offer? Vitalijs.
11-1 Copyright © 2010 Pearson Education, Inc. publishing as Prentice Hall Part IV: Start-up Financial Strategy Chapter 11: Funding the Technology Start-up.
HealthStart India Mr. Pradeep K. Jaisingh Chairman & Founder Enabling Healthcare Entrepreneurship.
China Healthcare Consulting Inc. Creating Value for Our Clients Boston Healthcare Associates, Inc. 75 Federal Street, 9 th Floor.
+ Role of Industry in Clinical Care, Research, and Education.
Albina Nikkonen Russian Private Equity and Venture Capital Market Review 2005 Russian Private Equity & Venture Capital Association.
NAIC Annual Meeting 2000 Private Equity Update 2000 Steven P. Galante Publisher, The Private Equity Analyst October 16, 2000.
The Small Business Innovation Research Program U S C E N G I N E E R I N G T E C H N O L O G Y T R A N S F E R C E N T E R A N A S A R E G I O N A L T.
How to Encourage Greater Private Equity Investment in Latin America Development of Non-Bank Financial Institutions in Latin America December 5, 2002 J.
SEEK is a drug-discovery group that uses a pioneering scientific and commercially-driven approach to create breakthrough medicines which address major.
Program Coordinator Medication Assistance Program Smilow Cancer Hospital at Yale New Haven Program Coordinator Medication Assistance Program Smilow Cancer.
Ed Vincent Gemma Postlethwaite State of the PE Market Global VC and PE Trends T H O M S O N F I N A N C I A L.
1Technology Transfer Tactics
“Managing a Startup in Turbulent Times” Satellite Broadcast Presented by Fred A. Middleton General Partner Sanderling Ventures June 6, 2001.
The Development of an Seed Investment Fund in New Zealand
NIHR Invention for Innovation (i4i)
The Dealy Strategy Group LLC Presentation to Health TechNet
CAPITAL FORMATION IN NORTH CAROLINA
Gestora brasileiro focada exclusivamente na área da saúde.
تأمین مالی طرح‌های خطر‌پذیر
Austin Technology Incubator Accelerating Innovation
فرآیند سرمایه گذاری مخاطره پذیر با سود بالا
Private Equity – Venture Capital Partnership for Success
Brendan Rauw, MBA, CLP Introduction
Tamar Raz, PHD.
“A new species has been discovered in the financial services industry which is peculiar to Australia. Whilst it may look the same as a number of other.
Presentation transcript:

TRSL Presentation December 5, 2005 Joseph F. Lovett Louisiana Fund I Managing Director

I.US Venture Capital II.Health Care Venture Capital III.Venture Capital Performance US Cal PERS PRIM – Massachusetts IV.Louisiana Fund I Venture Capital in Louisiana Team Limited Partners Portfolio Companies Summary

I. US Venture Capital 1,750 Venture Capital & Private Equity Partnerships Capitalization:$585 Billion Average Total Investment 1 year: $20 billion

$ in millions IndustryQ2YTD Q2 2004Q2 2005YTD Q Biotechnology$1,1012.8$1,902.6$1,122.2$1,753.8 Medical Devices$509.7$860.5$425.7$870.3 Healthcare Services $304.8$423.4$219.5$341.2 Total Health Industries VC Dollars $1827.3$3,186.5$1,767.4$2,965.2 Total VC Dollars $5,983.2$11,104.9$5,774.9$10,645.8

Hot areas of Investment in Health Care (10 year PWC Money Tree Survey) Individual disease management Cancer drug development Genomics Molecular Biology Innovative drug delivery methods Management of hospitals / clinics Obesity / weight loss treatments

III. Venture Capital Performance Fund Type1 Year3 Year5 Year10 Year20 Year Early/Seed VC2.1%-2.4%-10.5%48.8%20.2% Balanced VC11.7%7.6%-2.6%18.0%13.7% Later Stage VC8.8%3.2%-6.8%14.1%13.8% All Venture7.8%3.0%-6.3%25.8%16.0% Small Buyouts51.3%8.1%2.4%8.5%25.7% Med Buyouts29.3%6.4%-1.2%10.6%18.4% Large Buyouts21.4%12.9%3.0%10.9%14.7% Mega Buyouts26.9%11.1%3.6%8.1%11.0% All Buyouts26.9%11.0%2.9%9.0%13.8% Mezzanine9.7%4.2%3.2%6.6%9.1% All Private Equity20.4%8.2%0.1%12.7%13.8% NASDAQ0.4%12.0%-12.3%8.2%11.3% S&P %6.4%-3.9%8.1%10.6%

Calpers: AIM Program VC Funds $7.2 Billion in Generated Profits

FUNDYEARCOMMITED CAPITALCASH OUT & REMANING VALUEINTERIM IRR Alta Bio Pharma1998$50,000,000$81,205, % Alta California Pts1996$ $203,361, % Alta California Pts II1998$115,000,000$86,087,657(5.9)% Alta1996$30,000,000$37,247,3395.8% Alta V1992$35,000,000$83,043, % Golder,Toma III1994$25,000,000$514, % Golder, Toma V1997$40,000,000$64,664,6649.7% Hicks, Muse II1994$100,000,000$213,100, % Hicks, MUSE IIII1997$100,000,000$61,449,392(7.4%) KKR European I2001$75,000,000$93,677, % KKR Millennium2002$150,000,000$88,346, % Perseus Seros2001$40,000,000$37,342, % Sanderling IV1997$50,000,000$81,998, % Thomas Lee III1996$100,000,000$143,509, % Thomas LeeIII1998$100,000,000$134,272,5221.5% Warburg Pincus1990$100,000,000$236,300, % William Simon & Sons2001$25,000,000$30,069,6925.8%

State of Massachusetts PRIM $32.5 Billion 103 Venture Capital Funds 1986 – 1998 Returns: Majority between 10-30% Five Funds exceeded 50% Biggest Winner: Menlo Ventures IV : 127% Biggest Loser: Invexco ( a Houston oil & gas fund) (46%) Average annual Return: 12.7% US Thompson Venture Economics: 13.6% average

PRIM FUNDIRR Advent ESSF17% Advent GPE II22% Advent GPE III7% Advent International5% Advant International VI32% Fosrtman D&E III5% Fosrtman D&E IV20% Fosrtman D&E V18% Harbour Vest II9% Harbour Vest III14% Harbour Vest International11% KKR % KKR % KKR % KKR % NEA IV10% NEA VIII34% Tom Lee55% Tom Lee III31% Tom Lee IV(4)%

VENTURE CAPITAL INVESTMENTS: U.S. LOUISIANA No. Companies Investment $ No. Companies Investment $ ,320 $315,410,000, $616,000,000* Source: Price Waterhouse Coopers Data *One-half invested in one oil-related company, no companies in pharmaceuticals or biotechnology

US: Venture Capital Backed Companies Tandem Compaq Intel Genentech Amazon. COM Google Netscape Federal Express Oracle Sun Microsystems

Why is there a lack of venture capital in Louisiana?  Tradition  Venture Capital in Louisiana historically focused on late-stage investments  Similar to Boston in the 1980’s  Leadership Needed: - Harvard in Boston in 1988 with Medical Science Partners - LSU/LED/TRSL in Louisiana in 2004 with Louisiana Fund I

Sources in Louisiana for Early Stage Companies - Entrepreneurs - Universities, Academic Medical Centers, Research Centers and Companies - $ M per year in Research & Development Spending—50-60% in Life Sciences

Louisiana Fund I: Overview Louisiana needs a local early stage investment fund  Create home-grown companies located in Louisiana  Attract out-of-state companies to Louisiana  Investment in existing companies  Out-of-state investment funds will invest in Louisiana companies  LFI team experienced in working with early stage technologies and early stage companies

Benefits to Investors and Louisiana Attractive financial return on investment for investors Louisiana Fund I catalyst for creating new industries, companies and jobs across Louisiana Assist local economic development efforts Local companies based on locally developed technology will remain in Louisiana Attract Louisiana natives back home Out-of-state investors will invest in Louisiana companies Favorable publicity for investors

Louisiana Fund I: Scientific & Business Advisory Board Members Assist the Fund with due diligence Advice of key investment areas Serve on Boards of Companies Currently twelve members  MBAs -Board Members of Public Companies  PhDs-DMVs  CEOs-DDSs

Scientific and Business Advisory Board Current Members from Eli LillyUniversity of Pennsylvania GlaxoSmithKlineLouisiana Tech University Model SoftwareLSU Health Science Center, Shreveport Spirit-it Inc.Tulane University Aperion, LLCAnthem Capital

Portfolio Companies International Mezzo Systems—Nanotechnology & Micromachining Technology, LSU Incubator Company, LSU licensed technology Patient Care Inc. – Health Insurance advocacy services, New Orleans Esperance Biomedical, Pennington, LSU CAMD and LSU AG Center, Oncology Technology—lytic peptides for imaging and therapy for breast cancer metastases